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Abstract The long-term benefit of angiotensin-convert-
ing enzyme inhibitors in pediatric patients with aortic valve
regurgitation is under consideration. Eighteen patients with
mid to severe aortic valve regurgitation were retrospec-
tively evaluated. Echocardiographic parameters (left
ventricular end-diastolic diameter, shortening fraction, left
ventricular posterior wall thickness, and grade of aortic
valve regurgitation) were analyzed before and during
therapy with angiotensin-converting enzyme inhibitors.
Data are given as standard deviation scores (Z-scores)
derived from body surface-adjusted normal values. Median
(interquartile range) age at start of therapy was 8.4 (5.4 to
10.0) years, and total follow-up 2.3 (0.9 to 5.4) years. Left
ventricular end-diastolic diameter increased from 3.6 (2.3
to 4.5) to 3.7 (2.4 to 4.8), and left ventricular posterior wall
diameter decreased from 1.9 (1.1 to 3.0) to 1.1 (0.5 to 2.3).
Grade of aortic valve regurgitation increased from 3.5 (2.3
to 4.0) to 4.0 (2.0 to 4.0), and shortening fraction decreased
from 39% (34% to 43%) to 37% (34% to 42%). No sig-
nificant effect of angiotensin-converting enzyme inhibitors
on left ventricular dimensions or function was found in our
population of patients with mid to severe aortic valve
regurgitation. Angiotensin-converting enzyme inhibitors
may not alter left ventricular overload in pediatric patients
with aortic valve regurgitation.
Keywords Aortic valve regurgitation 
Angiotensin-converting enzyme inhibitor 
Echocardiography
Introduction
Chronic aortic valve regurgitation is characterized by a
diastolic backflow from the aorta into the left ventricle due
to malcoaptation of the aortic valve cusps [19]. The
regurgitant blood volume leads to a combined volume and
pressure overload of the left ventricle [6]. To compensate
this overload, the left ventricle dilates and hypertrophies
and ends up in an eccentric left ventricular hypertrophy
with the possible risk of left ventricular failure and death
[2–4, 19].
Different options for the pharmacological treatment of
aortic valve regurgitation such as diuretics, vasodilators,
angiotensin receptor blockers, and angiotensin-converting
enzyme inhibitors are available [1, 3, 11, 15–18, 20–22].
The reduction of volume load on the left ventricle by
afterload reduction is the foremost desired effect. This may
delay the progression of left ventricular dilatation, change
of left ventricular geometry, and increase in myocardial
mass [8, 14]. Angiotensin-converting enzyme inhibitors are
frequently used in pediatric patients with congenital heart
disease [1, 17–19]. Recent studies concerning the effect of
angiotensin-converting enzyme inhibitor therapy in adults
demonstrate controversial results [7, 11]. Pediatric studies
addressing therapy of isolated aortic valve regurgitation are
rare and limited.
Our objective was to evaluate the effect of angiotensin-
converting enzyme inhibitors on ventricular dimensions
and function in pediatric patients with mid to severe aortic
valve regurgitation.
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Materials and Methods
Patients
Between February 1988 and December 2005 all consecu-
tive patients (age \ 18 years) presenting with
hemodynamically isolated mid to severe aortic valve
regurgitation were included. Clinical charts and echocar-
diography data were analyzed retrospectively. Exclusion
criteria were patients with combined aortic valve stenosis
exceeding a mean gradient of 20 mm Hg, or peak gradient
of 40 mm Hg, and patients with additional hemodynami-
cally relevant cardiac defects such as ventricular septal
defect or mitral valve disease. Further exclusion criteria
were incomplete data and loss of follow-up.
Ethical approval for the study and data collection was
obtained according to the guidelines of the local ethics
committee.
Echocardiography
Echocardiographic analysis consisted of left ventricular end-
diastolic diameter, left ventricular posterior wall thickness,
shortening fraction, and aortic valve regurgitation mea-
surements and were performed in short-axis or long-axis
view in line with the recommendations of the American
Society of Echocardiography [13]. The grade of aortic valve
regurgitation was quantified by the area of regurgitant jet
from the apical view in relation to the area of the left ven-
tricular outflow tract (jet width ratio) and by the height of the
regurgitant jet into the left ventricle from the parasternal
long-axis view. Furthermore, pressure halftime, slope of
decay, and reversal blood flow in descending thoracic aorta
and abdominal aorta were measured. Classification of
grading of the severity of aortic valve regurgitation was
performed, based on recommendations of the American
Society of Echocardiography [10, 23].
Drug Administration
Clinical criterion for treatment with angiotensin-converting
enzyme inhibitors was a deterioration of left ventricular
function, an increase in left ventricular dimensions beyond
the 97th percentile, increasing grade of aortic valve
regurgitation, or onset of symptoms such as dyspnea on
exertion. As angiotensin-converting enzyme inhibitors,
captopril was given at a dose of 1 mg/kg/day for infants
and enalapril at a dose of 5–10 mg/m2/day for children [5].
Data Analysis
Data are presented as median (interquartile range). To
correct echocardiographic measurements for age and body
surface area, standardized deviation scores (Z-scores) were
calculated for normal values from Kampmann et al. [12].
Body surface area was calculated from height and weight
as described by DuBois [9].
We analyzed the echocardiographic parameters before
the start of angiotensin-converting enzyme inhibitor, at first
clinical control under treatment, and at the end of follow-
up.
Results
Our database revealed 24 patients with the diagnosis of mid
to severe aortic valve regurgitation. Six patients were
excluded due to incomplete data (n = 1), loss of follow-up
(n = 2), or other reasons (n = 3). Finally, 18 patients were
analyzed. Median (interquartile range) age at start of
angiotensin-converting enzyme inhibitor therapy was 8.4
(5.4 to 10.0) years, and time of follow-up 2.3 (0.9 to 5.4)
years. The cardiac diagnoses are reported in Table 1.
Time between start of angiotensin-converting enzyme
inhibitor and first clinical control under treatment was 3.8
(2.4 to 6.9) months. Table 2 reports changes among start of
angiotensin-converting enzyme inhibitor, first control
under treatment, and last control. Left ventricular posterior
wall diameter decreased under treatment. Left ventricular
end-diastolic diameter decreased at first control under
treatment but deteriorated until the end of follow-up. These
changes were not statistically significant. The grade of
aortic valve regurgitation deteriorated from 3.5 (2.3 to 4.0)
to 4.0 (2.0 to 4.0). The analysis of each single patient
shows that eight patients already had a grade of 4 at their
first control, and seven of eight patients had no improve-
ment under angiotensin-converting enzyme inhibitor
therapy. Four patients increased from grade 2 resp. 3 to
grade 3 resp. 4, whereas two patients showed no change
Table 1 Patient characteristics
Age at start of follow-up, yr (range)a 8.4 (5.4–10.0)
Time of follow-up, yr (range)a 2.3 (0.9–5.4)
Cardiac diagnosis
CAVD 12
TAC 2
TGA 1
TOF 1
Postinfectious 2
Note. CAVD, congenital aortic valve disease; postinfectious, status
after bacterial endocarditis or rheumatic fever; TAC, truncus arteri-
osus communis after surgical repair; TGA, transposition of the great
arteries after arterial switch; TOF, tetralogy of Fallot after surgical
repair
a Median (interquartile range)
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and only four patients showed an improvement from grade
3 resp. 4 to a grade of 2 (Fig. 1).
Discussion
In our study angiotensin-converting enzyme inhibitor ther-
apy in pediatric patients with mid to severe aortic valve
regurgitation did not show any significant improvement of
the left ventricular dilatation, left ventricular posterior wall
thickness, shortening fraction, or grade of aortic regurgita-
tion. Slight relief of the posterior wall thickness was evident
due to reduction of the systemic afterload. The degree of
aortic valve regurgitation was already mid to severe at the
start of angiotensin-converting enzyme inhibitor therapy, but
persisted as grade 4 aortic valve regurgitation in the majority
of our patients. Therefore, the treatment with angiotensin-
enzyme inhibitors showed no significant effect on the degree
of aortic valve regurgitation. Left ventricular end-diastolic
diameter showed an improvement at the first control after
start of treatment, but increased progressively in the fol-
lowing clinical controls as reported in Table 2.
The first study concerning positive effects of angioten-
sin-converting enzyme inhibitors in adults with aortic valve
regurgitation was published by Reske et al. [20]. In 1994,
the positive effect of unloading therapy was confirmed by
Lin et al. [15] and by Schon et al. [21]. The study by Lin
et al. [15] compared enalapril with hydralazine. Both drugs
showed a positive effect. Schon et al. [21] analyzed
hemodynamic and morphologic changes after 1 year of
angiotensin-converting enzyme inhibition with quinapril,
although there was no control group.
The first study in pediatric patients concerning the
positive effect of angiotensin-converting enzyme inhibitor
therapy was carried out by Alehan et al. in 1998 [1]. Their
study showed that in pediatric patients with chronic aortic
regurgitation, long-term angiotensin-converting enzyme
inhibitor therapy reduces regurgitant volume and favorably
affects left ventricular volumes, dimensions, and hyper-
trophy. As study limitations they declared the absence of a
control group and the rather short observation time of
1 year. However, most of their patients had aortic regur-
gitation due to rheumatic heart disease and the
morphologic and functional changes may also be due to
spontaneous myocardial recovery.
In 2000, Mori et al. [18] also reported positive effects
during growth. However, they included patients with aortic
valve regurgitation and patients with mitral valve regur-
gitation in their study. In contrast, the study in adults by
Evangelista et al. [11]. was the first to report no difference
in the clinical course of three groups. The first group was
untreated, the second group was treated with nifedipine,
and the third group was treated with enalapril. They ana-
lyzed probability of aortic valve replacement and left
ventricular variables like diameter and ejection fraction in
patients with asymptomatic, chronic, severe aortic valve
regurgitation.
Numerous studies are available concerning afterload
reduction with vasodilators or angiotensin-converting
enzyme inhibitors in adults. The conflicting results may be
due to methodical factors such as different patient char-
acteristics, different drugs and dosages, or different
hemodynamic and echocardiographic parameters.
Regarding the potential side effects and the costs of
angiotensin-converting enzyme inhibitors, whether an
application is justified must be carefully considered.
Table 2 Comparison of echocardiographic parameters at start of follow-up, first control under treatment, and last control under treatment for
patients with aortic valve regurgitation treated with ACE inhibitors
Start of ACE First control, treatment Last control, treatment
LVEDD, Z-score 3.6 (2.3–4.5) 3.3 (2.8–4.0) 3.7 (2.4–4.8)
LVPWD, Z-score 1.9 (1.1–3.0) 1.5 (0.5–2.5) 1.1 (0.5–2.3)
AR grade 3.5 (2.0–4.0) 4.0 (2.0–4.0) 4.0 (2.0–4.0)
SF, % 39.0 (33.5–43.0) 39.5 (35.3–41.8) 36.5 (34.3–41.8)
Note. ACE, angiotensin-converting enzyme; LVEDD, left ventricular end-diastolic diameter; LVPWD, left ventricular posterior wall diameter;
AR, aortic valve regurgitation; SF, shortening fraction; Z-score, standardized deviation score. Median (interquartile range)
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Fig. 1 Grade of aortic valve regurgitation at start of angiotensin-
converting enzyme (ACE) inhibitor treatment; 4 months later, under
treatment; and at last follow-up under treatment
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Study Limitations
The heterogeneous group of patients in terms of age and
principal diagnosis, small patient number, progressed grade
of aortic regurgitation, retrospective study design, and lack
of invasive hemodynamic data are study limitations.
Conclusion
No effect of angiotensin-converting enzyme inhibitor
therapy was shown in a small group of pediatric patients
with mid to severe aortic valve regurgitation. There was
only a possible effect on posterior wall diameter. In view of
our results, the lack of long-term follow-up studies with
large patient cohorts, and the controversial study results in
adults, a prospective long-term multicenter follow-up study
will be required, to increase the number of patients and to
define a homogeneous study group of patients [16].
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